You're seeing the preview. Pro unlocks the full CrowdMed teardown, the rebuild plan, every technical spec in the database, and 5 fresh report requests each month.
This report was generated by our Deep Research agent and may contain mistakes.
Did we get something wrong? DM @oscrhong and we'll fix it ASAP!
If you only have a few minutes to spare, here’s what investors, operators, and founders should know about CrowdMed (W13).
CrowdMed was a crowdsourced diagnosis marketplace where medical detectives reviewed hard cases and a prediction market ranked likely diagnoses, from YC Winter 2013. CrowdMed was founded in 2012 to use crowdsourcing and prediction markets for difficult medical cases. [1]
CrowdMed was right that rare cases need more minds, but the product's trust boundary was wrong. The crowd could suggest possibilities; the health system still controlled diagnosis, reimbursement, and liability. The outcome shows the difference between product need and standalone company structure.
CrowdMed's origin was specific rather than generic. CrowdMed was founded in 2012 to use crowdsourcing and prediction markets for difficult medical cases. [1] The early product insight was this: CrowdMed attacked a real failure in healthcare, but the model asked patients to trust strangers and pay out of pocket for advice that still had to be validated by clinicians.
Jared Heyman started CrowdMed after his sister spent more than three years and over $100,000 seeking a diagnosis. [2] That setup mattered because the company was not selling a thin interface. It asked users to trust a new workflow for a decision that already had entrenched habits.
CrowdMed told WIRED: "Instead of relying on individual physicians, CrowdMed harnesses the collective intelligence of hundreds of 'medical detectives'" [4] Jared Heyman told TEDMED profile: "medical detectives could help solve difficult medical mysteries online" [2] Those quotes define the company better than a feature list: CrowdMed tried to compress an emotionally noisy decision into a structured product.
The founding gap is also worth stating. Public sources do not fully explain every early team decision, board conversation, or financing constraint. The available record is strongest on product shape, funding or acquisition events, and the strategic reason the idea ended up inside a larger system.
CrowdMed built a crowdsourced diagnosis marketplace where medical detectives reviewed hard cases and a prediction market ranked likely diagnoses. The first user experience was designed to replace an inefficient default: patients who had already spent years, money, and emotional energy on unresolved diagnoses; later enterprise prospects included insurers and self-insured employers. The product's promise was not novelty for its own sake. It was a cleaner decision loop.
The key workflow had three parts. First, the user supplied context. Second, the system turned that context into a ranked recommendation, assessment, or plan. Third, the user or buyer acted on the output with less search cost. That pattern is visible across the public facts: CrowdMed launched public beta at TEDMED in 2013. [4]
The product differed from alternatives because it packaged judgment, not just information. Directories, search results, and generic software leave the hard ranking work to the user. CrowdMed tried to own the ranking layer. In complex medical case navigation, that is valuable only when the ranking is trusted and tied to a transaction or operating workflow.
The company raised $2.4 million from Patrick Dempsey, NEA, Andreessen Horowitz, Greylock, SV Angel, Khosla Ventures, and Y Combinator. [3] That evidence suggests the product had real substance. The harder question was whether that substance created a standalone distribution advantage.
Patients who had already spent years, money, and emotional energy on unresolved diagnoses; later enterprise prospects included insurers and self-insured employers.
Read the complete post-mortem, the rebuild playbook, and the exact reasons CrowdMed is still worth studying now.